Objectives To build a lamotrigine (LTG) physiologically based pharmacokinetic (PBPK) model (LTG PBPK) and compare it to the clinical data from South Asian Indian patients use this understand drug interactions of LTG explore optimal doses. Methods Material The PBPK was developed using PK-Sim software platform qualified with plasma concentration an study. European population database chosen as pa...

background caesarian section is a commonplace surgery in females for which spinal anesthesia is the preferred method. the local anesthetic medications used in the surgery are often associated with complications such as nausea, vomiting, dyspnea, hypotension, and bradycardia. in the present study, we decreased the dose of the anesthetic drug and added an opioid instead. objectives we tried to fi...

ATYPICAL NEUROLEPTICS HAVE BECOME THE FIRST LINE OF TREATMENT FOR PSYCHOTIC DISORDERS, BUT SOME QUESTIONS REMAIN: what are their optimal dosages and is more medication more efficacious? For clozapine, it is recommended to aim for a plasma level above 350 ng/mL for nonresponders and partial responders. It should be specified that this plasma level should be obtained exactly 12 h after the last d...

Antimicrobial pharmacokinetic-pharmacodynamic (PK/PD) science and clinical trial simulations have not been adequately applied to the design of doses and dose schedules of antituberculosis regimens because many researchers are skeptical about their clinical applicability. We compared findings of preclinical PK/PD studies of current first-line antituberculosis drugs to findings from several clini...

To investigate why responses of mast cells to antigen-induced IgE receptor (FcεRI) aggregation depend nonlinearly on antigen dose, we characterized a new artificial ligand, DF3, through complementary modeling and experimentation. This ligand is a stable trimer of peptides derived from bacteriophage T4 fibritin, each conjugated to a hapten (DNP). We found low and high doses of DF3 at which degra...

The optimal doses of angiotensin-converting enzyme inhibitors (ACE-I) and/or angiotensin II receptor blockers (ARBs) for maximal reduction in urinary protein excretion are not known. Moreover, beneficial effects from ARBs, such as tissue protection owing to a more complete blockade of the renin-angiotensin-aldosterone system (RAAS), may be independent of blood pressure-lowering by ARBs. In this...